These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 22858313)

  • 21. Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
    Izawa N; Onozawa Y; Hikosaka T; Hamauchi S; Tsushima T; Todaka A; Machida N; Haraguchi Y; Ogawa H; Nishimura T; Nakagawa M; Fuke T; Iida Y; Kamijo T; Onitsuka T; Boku N; Yasui H; Yokota T
    Int J Clin Oncol; 2015 Jun; 20(3):455-62. PubMed ID: 25248339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
    Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
    Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
    Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
    Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome with neck dissection after chemoradiation for N3 head-and-neck squamous cell carcinoma.
    Igidbashian L; Fortin B; Guertin L; Soulières D; Coulombe G; Belair M; Charpentier D; Tabet JC; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):414-20. PubMed ID: 19775825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Planned post-chemoradiation neck dissection: significance of radiation dose.
    Stenson KM; Huo D; Blair E; Cohen EE; Argiris A; Haraf DJ; Vokes EE
    Laryngoscope; 2006 Jan; 116(1):33-6. PubMed ID: 16481805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension].
    Lévy A; Blanchard P; Janot F; Temam S; Bourhis J; Daly-Schveitzer N; Tao Y
    Cancer Radiother; 2014 Jan; 18(1):1-6. PubMed ID: 24309002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer.
    Rengan R; Pfister DG; Lee NY; Kraus DH; Shah JP; Shaha AR; Ben-Porat LS; Zelefsky MJ
    Am J Clin Oncol; 2008 Oct; 31(5):465-9. PubMed ID: 18838883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
    J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
    Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
    Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
    Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
    Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
    Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection.
    Smyth JK; Deal AM; Huang B; Weissler M; Zanation A; Shores C
    Laryngoscope; 2011 Sep; 121(9):1881-7. PubMed ID: 21997727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node metastasis in sinonasal squamous cell carcinoma treated with IMRT/3D-CRT.
    Guan X; Wang X; Liu Y; Hu C; Zhu G
    Oral Oncol; 2013 Jan; 49(1):60-5. PubMed ID: 22884302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nodal response to chemoselection predicts the risk of recurrence following definitive chemoradiotherapy for pharyngeal cancer.
    Hanai N; Ozawa T; Hirakawa H; Suzuki H; Fukuda Y; Hasegawa Y
    Acta Otolaryngol; 2014 Aug; 134(8):865-71. PubMed ID: 25022795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck.
    Lau H; Phan T; Mackinnon J; Matthews TW
    Arch Otolaryngol Head Neck Surg; 2008 Mar; 134(3):257-61. PubMed ID: 18347249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
    Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
    Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Ready NE; Rathore R; Johnson TT; Nadeem A; Chougule P; Ruhl C; Radie-Keane K; Theall K; Wanebo HJ; Marcello J; Kennedy T
    Am J Clin Oncol; 2012 Feb; 35(1):6-12. PubMed ID: 21293244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
    McHam SA; Adelstein DJ; Rybicki LA; Lavertu P; Esclamado RM; Wood BG; Strome M; Carroll MA
    Head Neck; 2003 Oct; 25(10):791-8. PubMed ID: 12966502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.